U.S. Markets closed

Momenta Pharmaceuticals, Inc. (MNTA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
52.480.00 (0.00%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close52.48
Bid0.00 x 36200
Ask0.00 x 2200
Day's Range52.46 - 52.50
52 Week Range15.31 - 52.53
Avg. Volume3,471,613
Market Cap6.243B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateFeb 24, 2021 - Mar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.50
  • Hedge Funds Made A Bundle From Momenta Pharmaceuticals, Inc. (MNTA)
    Insider Monkey

    Hedge Funds Made A Bundle From Momenta Pharmaceuticals, Inc. (MNTA)

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • Moody's

    Johnson & Johnson -- Moody's assigns Aaa to J&J's sr. notes; outlook negative

    Moody's Investors Service ("Moody's") assigned a Aaa rating to the new senior unsecured notes offering of Johnson & Johnson ("J&J"). There are no changes to J&J's existing ratings including the Aaa senior unsecured long-term rating and the Prime-1 short term rating. J&J's Aaa rating reflects the company's large scale and market presence, its strong product and geographic diversity, and its high margins.

  • GlobeNewswire

    Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson

    Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion of its sale to Johnson & Johnson for $52.50 per share, totaling approximately $6.5 billion. The all-cash tender offer by Vigor Sub, Inc. (“Vigor”), a wholly owned subsidiary of Johnson & Johnson, for all outstanding shares of Momenta common stock for $52.50 per share expired at 12:00 a.m. (midnight), New York City time, at the end of the day on September 30, 2020.